Q3 FY23 Earnings Presentation
Q3 FY23 Financial summary
Revenue by segment
Diabetes
$570M
-2.4% Y/Y Rep
+3.3% Y/Y Org
Total MDT
$7,727M
-0.5% Y/Y Rep
+4.1% Y/Y Org
Cardiovascular
$2,772M
+1.0% Y/Y Rep
+6.5% Y/Y Org
Medical Surgical
$2,137M
-6.7% Y/Y Rep
-1.6% Y/Y Org
-0.7% ex-Vents Y/Y Org
1)
2)
Data has been intentionally rounded to the nearest million and, therefore, may not sum.
Operating cash flows less property, plant, and equipment additions.
6 | Q3 FY23 Earnings Presentation | February 21, 2023
汁
Table of Executive Portfolio Financial Guidance &
Contents Summary Highlights Highlights Assumptions
ESG Appendix
Revenue¹ by geography
United States
$4,062M
+3.1% Y/Y Rep
+2.5% Y/Y Org
O
Non-U.S. Developed
$2,294M
-5.9% Y/Y Rep
+6.0% Y/Y Org
Emerging Markets
$1,371M
-1.0% Y/Y Rep
+5.4% Y/Y Org
GAAP
Non-GAAP
Neuroscience
$2,248M
+4.9% Y/Y Rep
Diluted EPS
$0.92
$1.30
Y/Y%
-16%
-4%
+7.3% Y/Y Org
CC Y/Y %
N/A
+1%
Cash flow from
operations YTD
$3.6B
Free cash flow² YTD
$2.5B
MedtronicView entire presentation